SCHEMBL8534660

SCHEMBL8534660

CCCc1cc(C=O)cc(C(C)(C)C)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 2/20 0.46
GABBR1 Q9UBS5 2/20 0.46
HSPA5 P11021 2/20 0.42
HIF1A Q16665 3/20 0.41
CYP1A2 P05177 3/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP3A4 P08684 2/20 0.41
MAPT P10636 2/20 0.41
TSHR P16473 2/20 0.41
BLM P54132 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
USP2 O75604 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.41
NR1I2 O75469 1/20 0.41
HMGCR P04035 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27418086 0.84 KDM4E (0.45) CYP1A2ALDH1A1CYP3A4HMGCRCYP2C9
SCHEMBL85764 0.80 GABBR2 (0.66) GABBR2GABBR1HIF1ACYP1A2KMT2A
SCHEMBL1105055 0.79 GABBR2 (0.45) GABBR2GABBR1HSPA5HIF1ACYP1A2
Hydrochloric Acid SCHEMBL31385524 0.79 GABBR2 (0.63) GABBR2GABBR1HIF1ACYP1A2KMT2A
Water SCHEMBL1502206 0.79 GABBR2 (0.63) GABBR2GABBR1HIF1ACYP1A2KMT2A
Water SCHEMBL1502204 0.79 GABBR2 (0.63) GABBR2GABBR1HIF1ACYP1A2KMT2A
SCHEMBL11864278 0.77 GABBR2 (0.50) GABBR2GABBR1HIF1ACYP1A2KMT2A
SCHEMBL1823153 0.77 PTGS1 (0.49) GABBR2GABBR1CYP1A2CYP2C9CYP2C19
SCHEMBL1823151 0.77 PTGS1 (0.49) GABBR2GABBR1CYP1A2CYP2C9CYP2C19
SCHEMBL11870637 0.77 GABBR2 (0.53) GABBR2GABBR1HIF1ACYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0434394-B1 Compounds for treating inflammatory bowel disease LILLY CO ELI (US) 1998-08-05 EP disclosed
US-5731336-A USING ARYL-SUBSTITUTED RHODAMINES ELI LILLY AND COMPANY (US) 1998-03-24 US disclosed
WO-1996022772-A1 METHOD FOR TREATING MULTIPLE SCLEROSIS ELI LILLY AND COMPANY (US) 1996-08-01 WO disclosed
EP-0722729-A2 Aryl-substituted rhodanines for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1996-07-24 EP disclosed
US-5387690-A Method of treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1995-02-07 US disclosed
US-5216002-A Using benzyl substituted rhodanine derivatives as pure enantiomeric form ELI LILLY AND COMPANY (US) 1993-06-01 US disclosed
US-5158966-A Aryl-substituted rhodanine derivatives THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-10-27 US disclosed
EP-0500337-A1 Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-08-26 EP disclosed
EP-0434394-A2 Compounds for treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1991-06-26 EP disclosed